Company intelligence / Profile preview

Zepto Life Technology

Saint Paul, Minnesota, United Stateszeptolife.com ↗

Ownership: Private
Employees: ~29
Development stage: Commercial

Overview

Zepto Life Technology has developed a proprietary GMR-based lab-on-a-chip diagnostic system with high sensitivity (>95%) and rapid turnaround (<90 minutes), targeting multiplexed disease biomarker detection at point-of-care. Their FungiFlex™ panel can identify >95% of common invasive fungal pathogens. The company provided COVID‑19 PCR and antigen tests during the pandemic but their core molecular diagnostic platforms are still in advanced development or regulatory submission stages.

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: DeviceDiagnostic platform (Lab-on-a-chip)Nanoparticle-based assay (Magnetic nanoparticle immunoassay)Molecular diagnostics platform
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Zepto Life Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zepto Life Technology.

Explore the full profile